Pillstats
Rx only · Injection, Solution · Subcutaneous

Dupilumab

Brands: Dupixent · Dupilumab

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US5 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCD11AH05
RxCUI (US)1876376
US makers1 labelers
Packages10
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$400.30$800.61$1200.91$1601.22Jan 2026Jun 2026Jul 2026
$1392.364
Latest avg · Jul 22, 2026
+0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

118K236K353K471K2025 Q12025 Q22025 Q32025 Q42026 Q1
387K
Rx · 2026 Q1
1.5M
Units dispensed
+11%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Sanofi-Aventis U.S. LLCunknown10SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.